Drug Trial Radar · NCT04176120
Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)
Last checked: Nov 20, 2026Latest source record: Jun 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
220
Actual
Start
Jul 1, 2020
Primary completion
Jan 25, 2024
Study completion Jun 12, 2024
Sponsor
- Lead sponsor
- BioTissue Holdings, IncIndustry
- Sponsor type
- Industry
- First posted
- Nov 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, will result in a higher rate of wounds showing complete healing within 26 weeks of initiating therapy, compared with standard care alone. This confirmatory Phase 3 study examines a population of diabetic foot ulcer patients having adequate perfusion, with or without neuropathy, and a high suspicion of associated osteomyelitis in a complex, high grade wound.
Conditions
- Diabetic Foot Infection
- Non-healing Wound
- Non-healing Diabetic Foot Ulcer
Interventions
TTAX01Biological
TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).
Standard CareOther
Standard care is defined in this protocol to consist of the following: * Debridement; * Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited; * Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate; * A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin; * Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and, * Appropriate use of systemic antibiotics.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete wound healingTime frame: over 26 weeks
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Center for Clinical Research, Inc
San Francisco, California
UCLA Olive View
Sylmar, California
University of Miami
Miami, Florida
Paley Orthopedic & Spine Institute
West Palm Beach, Florida
Rosalind Franklin University
North Chicago, Illinois
Ochsner Medical Center
New Orleans, Louisiana
Mount Sinai West
New York, New York
University of North Carolina
Chapel Hill, North Carolina
University Hospitals Richmond Medical Center
Richmond Heights, Ohio
Oregon Health & Science University
Portland, Oregon
Vanderbilt University Medical Center
Nashville, Tennessee
JPS
Fort Worth, Texas
Futuro Clinical Trials, LLC
McAllen, Texas
Bio-X-Cell Research
San Antonio, Texas
Foot & Ankle Institute
St. George, Utah
Carilion Clinic
Roanoke, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.